

**GF/B45/EDP04**

***Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Uganda)***

Approved on 1 July 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding USD 35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER04; and
3. Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

**Table 1: Secretariat's Recommendation on Funding from C19RM<sup>1</sup>**

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country / Multicountry	Grant name	Currency	C19RM 2020 carry-over amount <sup>2</sup>	Previously approved C19RM 2021 award <sup>3</sup>	<u>C19RM 2021 recommended amount for Board approval</u>	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding including 2020 carry-over	C19RM 2021 Unfunded Demand
<a href="#">Uganda</a>	UGA-C-TASO	US\$	199,205	0	<b>6,604,236</b>	126,862,493	21.91%	134,642,193	337,921,514
	UGA-H-MOPED	US\$	7,580,494	0	<b>120,258,258</b>				

<sup>1</sup> The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

<sup>2</sup> Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

<sup>3</sup> This includes Secretariat approved Fast-track and Full Funding Request awards, as well as awards previously approved by the Board.